Parexel hires Imogene Grimes, a leading biostatistician with more than 25 years of experience, as vice president of data sciences strategic services.
Boston, MA-April 30, 2008-Parexel, a leading global biopharmaceutical services organization, has appointed Imogene Grimes to vice president of data sciences strategic services. Dr. Grimes, a leading biostatistician with more than 25 years of experience, is contributing to the continued expansion of Parexel's data science services, including data management, biostatistics, and applications of information technology to the clinical development process. Her responsibilities include advising clients on clinical study design, analysis methodology, and related regulatory guidelines. Dr. Grimes provides support for strategic data services, such as preparation of integrated data files suitable for registration packages and preparation of electronic submissions, compliant with regulatory expectations.
"The biopharmaceutical industry is undertaking more complex clinical research such as using adaptive designs with the potential to detect safety and efficacy signals earlier. Dr. Grimes will bring experience with advanced statistical methods to Parexel, which we believe will be a tremendous asset to our clients in bringing novel treatments to patients sooner,” said Mark A. Goldberg, MD, president of clinical research services and Perceptive Informatics at Parexel.
"Parexel has one of the industry's largest and most deeply expert data sciences departments,” said Barbara Tardiff, MD, corporate vice president of data sciences, clinical research services, Parexel. "We look forward to the contributions Dr. Grimes will make to further strengthen and expand our strategic data and informatics capabilities for clients globally as well as supporting our e-submissions strategies.”
Prior to joining Parexel, Dr. Grimes served as vice president, statistics, data management and informatics at Regeneron Pharmaceuticals, where she provided statistical and data management expertise for all phases of drug development research. Previously, she was vice president statistics and data management at Yamanouchi Pharma America, now Astellas Pharma, and held senior management positions at Pfizer and GlaxoSmithKline.
Dr. Grimes holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill, and Master's and Bachelor's degrees from the University of North Carolina at Greensboro. A focus of Dr. Grimes' career has been regulatory submissions of marketing applications using electronic media and in particular ensuring an understanding of regulatory expectations for statistics and data management. She currently serves as a board member of the Data Quality Research Institute, and is a member of several industry organizations including the American Statistical Association and The International Biometric Society. Dr. Grimes has presented several training courses and has authored numerous articles on data management and statistics topics.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.